Cleavable linkers in antibody-drug conjugates

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Antibody-Drug Conjugates (ADCs) are a significant therapeutic class for cancer treatment.
• Linker technology is critical for ADC efficacy and safety.
• Cleavable linkers enable controlled drug release at the target site, distinguishing them from non-cleavable types.

Purpose of the Study:

• To review recent advances in cleavable linker technologies for Antibody-Drug Conjugates (ADCs).
• To highlight the importance of linker properties in ADC therapeutic success.
• To discuss the interplay between linker development and understanding ADC mechanisms of action.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of emerging and established cleavable linker strategies.
• Synthesis of information on drug release mechanisms and biological processes.

Main Results:

• The majority of ADCs in development utilize cleavable linkers.
• New drug release methods are continually being developed.
• Understanding biological processes informs linker technology advancements.

Conclusions:

• Cleavable linker technology is a rapidly evolving field within ADC development.
• Continued innovation in linker design is essential for improving ADC therapeutics.
• Advances in cleavable linkers contribute to more effective cancer treatments.